Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Non-Current Liabilities (2018 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Total Non-Current Liabilities over the past 13 years, most recently at $166.9 million for Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities fell 11.21% year-over-year to $166.9 million; the TTM value through May 2025 reached $166.9 million, down 11.21%, while the annual FY2025 figure was $166.9 million, 11.21% down from the prior year.
  • Total Non-Current Liabilities for Q2 2025 was $166.9 million at Lifecore Biomedical, Inc. \De\, roughly flat from $166.4 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $301.6 million in Q1 2021 and troughed at $153.6 million in Q2 2023.
  • A 5-year average of $203.9 million and a median of $188.2 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 39.95% in 2022 and later grew 22.43% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $264.0 million in 2021, then decreased by 22.47% to $204.6 million in 2022, then fell by 0.66% to $203.3 million in 2023, then dropped by 15.23% to $172.3 million in 2024, then dropped by 3.14% to $166.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for LFCR at $166.9 million in Q2 2025, $166.4 million in Q1 2025, and $172.3 million in Q4 2024.